Introduction {#sec1-0300060519884197}
============

Hearing loss (HL) is the most frequent sensory deficit in humans, with a prevalence of around 1/1000 in newborns.^[@bibr1-0300060519884197],[@bibr2-0300060519884197]^ Approximately 50% to 60% of hearing loss cases are caused by genetic factors.^[@bibr3-0300060519884197]^ The genetic mode of HL inheritance can be autosomal recessive, autosomal dominant, mitochondrial, or X/Y-linked. To date, 121 genes have been reported to be associated with hearing loss ([http://hereditaryhearingloss.org/](https://hereditaryhearingloss.org/)): 45 are autosomal dominant genes,71 are autosomal recessive, and 5 are X-linked. However, most of these genes have only been reported in one or a few families.^[@bibr4-0300060519884197]^ Epidemiological studies showed that variants in *GJB2*, *SLC26A4*, and 12S rRNA genes are highly correlated with hereditary HL.^[@bibr2-0300060519884197]^ The most frequent genetic cause of HL is variants in *GJB2*, and most of these cases occur with non-progressive HL. Variants in *SLC26A4*, *CDH23*, and *MYO3A* were also shown to be associated with naturally occurring progressive HL.^[@bibr5-0300060519884197],[@bibr6-0300060519884197]^

The genetic diagnosis of HL is very important because the findings can be used to aid treatment decisions, and provide prognostic information and genetic counseling for the patient's family.^[@bibr7-0300060519884197]^ Here, we describe a young couple with HL in whom the husband carried compound heterozygous variants of *GJB2*, and the wife had an extremely rare form of deafness and compound heterozygous variants of *LOXHD1*. We provided genetic counseling for this couple and followed them up during their pregnancy.

Patients and methods {#sec2-0300060519884197}
====================

Study population {#sec3-0300060519884197}
----------------

We recruited a young Chinese couple (husband: 27 years old; wife: 25 years old) with congenital HL and 100 healthy controls (aged 25--30 years) from Gansu Provincial Maternal and Child Health Care Hospital. The couple had been married for 6 months and requested pre-pregnancy genetic counseling. The study was in accordance with the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of Gansu Provincial Maternal and Child Health Care Hospital. Written informed consent was obtained from all participants.

Sample collection and genomic DNA preparation {#sec4-0300060519884197}
---------------------------------------------

Blood samples (2--3 mL) were collected from the probands and their parents and control individuals. Genomic DNA was extracted using a Tiangen DNA extraction kit (Tiangen Biotech, Beijing, China) according to the manufacturer's instructions and quantified spectrophotometrically.

Targeted next-generation sequencing (NGS) and Sanger sequencing {#sec5-0300060519884197}
---------------------------------------------------------------

First, the coding exon and flanking sequences of *GJB2* were screened by PCR and direct sequencing using primers and conditions described in [Table 1](#table1-0300060519884197){ref-type="table"}. If no *GJB2* variant was found, targeted capture of candidate disease genes (n = 165, [Table 2](#table2-0300060519884197){ref-type="table"}) was performed using a GenCap custom enrichment kit (MyGenostics, Beijing, China). Briefly, 1 μg of DNA library was mixed with BL buffer and a GenCap hypercholesterolemia probe (MyGenostics) and heated in a PCR cycler at 95°C for 7 minutes then 65°C for 2 minutes. A total of 23 μL HY buffer (pre-warmed to 65°C; MyGenostics) was added and the mixture was incubated at 65°C for 22 hours for hybridization. MyOne beads (50 μL; Thermo Fisher Scientific Inc., Rockford, IL, USA) were washed three times in 500 μL binding buffer (1×) and re-suspended in 80 μL binding buffer (1×). Next, 64 μL binding buffer (2×) was added and the mixture was transferred into a tube containing 80 μL MyOne beads, and spun for 1 hour on a rotator. The beads were then washed once with WB1 buffer at room temperature for 15 minutes and three times with WB3 buffer at 65°C for 15 minutes. Elution buffer was used to elute the bound DNA, which was amplified as follows: 98°C for 30 seconds then 15 cycles of 98°C for 25 seconds, 65°C for 30 seconds, and 72°C for 30 seconds, followed by 72°C for 5 minutes. PCR products were purified using SPRI beads (Beckman Coulter Inc., Brea, CA, USA) following the manufacturer's protocol. Enrichment libraries were sequenced on an Illumina HiSeq 2000 sequencer (Illumina, San Diego, CA, USA) for 100-bp paired reads.

###### 

Primers and PCR conditions for *GJB2* and *LOXHD1*.

![](10.1177_0300060519884197-table1)

  Primer name   Sequence (5′--3′)        Product size (bp)    Amplification reaction conditions
  ------------- ------------------------ -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GJB2-F        CATGCTTGCTTACCCAGACTCA   873                  95°C for 5 minutes, then 20 cycles of 94°C for 30 seconds, 62°C for 45 seconds, and 72°C for 1 minute95°C for 5 minutes, then 15 cycles of 94°C for 30 seconds, 58°C for 45 seconds, and 72°C for 1 minute.
  GJB2-R        TAGCGACTGAGCCTTGACAGC                         
  GJB2-S1       TGGGTTTTGATCTCCTCGATG    Sequencing primers   
  GJB2-S2       GCCTACCGGAGACATGAGAAG                         
  LOXHD1-E14F   GGTAGTAGGGCTGGGTCTTCC    355                  
  LOXHD1-E14R   AGTTGCCTAACCCATCAGCTC                         
  LOXHD1-E19F   CACCAACTCCACGACAAGTTC    594                  
  LOXHD1-E19R   GAGGTGGTGGAAGGATCTGAG                         

GJB2-S1 and GJB2-S2 are the sequencing primers for *GJB2*.

###### 

Genes in the hearing loss panel.

![](10.1177_0300060519884197-table2)

  --------------------------------------------- ------------ ----------- ----------- ------------ ----------- ------------
  Nuclear genes associated with hereditary HL                                                                 
  *ACTG1*                                       *ADGRV1*     *ALX3*      *BSND*      *CABP2*      *CCDC50*    *CDH23*
  *CEACAM16*                                    *CHD7*       *CIB2*      *CLDN14*    *CLPP*       *CLRN1*     *COCH*
  *COL11A1*                                     *COL11A2*    *COL1A1*    *COL1A2*    *COL2A1*     *COL4A3*    *COL4A4*
  *COL4A5*                                      *COL4A6*     *COL9A1*    *COL9A2*    *CRYM*       *DFNB59*    *DIABLO*
  *DIAPH1*                                      *DIAPH3*     *DSPP*      *ECM1*      *EDN3*       *EDNRB*     *ELMOD3*
  *ESPN*                                        *ESRRB*      *EYA1*      *EYA4*      *FGF3*       *FGF8*      *FGFR1*
  *FGFR3*                                       *FLNA*       *FOXI1*     *FREM1*     *FXN*        *GATA3*     *GIPC3*
  *GJB1*                                        *GJB2*       *GJB3*      *GJB6*      *GLYAT*      *GPSM2*     *GRHL2*
  *GRXCR1*                                      *GSDME*      *HARS*      *HARS2*     *HGF*        *HMX1*      *HOXA2*
  *HSD17B4*                                     *IL13*       *ILDR1*     *KARS*      *KCNE1*      *KCNJ10*    *KCNQ1*
  *KCNQ4*                                       *KITLG*      *KRT9*      *LAMA3*     *LARS2*      *LHFPL5*    *LOXHD1*
  *LRTOMT*                                      *MARVELD2*   *MIR96*     *MITF*      *MPZ*        *MSRB3*     *MYH14*
  *MYH9*                                        *MYO15A*     *MYO1A*     *MYO1E*     *MYO3A*      *MYO6*      *MYO7A*
  *NDP*                                         *NDRG1*      *NEFL*      *NELL2*     *NF2*        *OPA1*      *OTOA*
  *OTOF*                                        *OTOG*       *OTOGL*     *P2RX2*     *PABPN1*     *PAX3*      *PCDH15*
  *PCDH9*                                       *PDZD7*      *PMP22*     *PNPT1*     *POLR1C*     *POLR1D*    *POU3F4*
  *POU4F3*                                      *PROK2*      *PROKR2*    *PRPS1*     *PTPN11*     *PTPRQ*     *PTPRR*
  *RDX*                                         *RPGR*       *SALL1*     *SALL4*     *SEC23A*     *SEMA3E*    *SERPINB6*
  *SIX1*                                        *SIX5*       *SLC17A8*   *SLC19A2*   *SLC26A4*    *SLC26A5*   *SMAD4*
  *SMPX*                                        *SNAI2*      *SOX10*     *STRC*      *TBC1D24*    *TCIRG1*    *TCOF1*
  *TECTA*                                       *TIMM8A*     *TJP2*      *TMC1*      *TMEM126A*   *TMIE*      *TMPRSS3*
  *TMPRSS4*                                     *TNC*        *TPRN*      *TRIOBP*    *TRMU*       *TSPEAR*    *TYR*
  *USH1C*                                       *USH1G*      *USH2A*     *WFS1*      *WHRN*                   
  Mitochondrial gene                                                                                          
  *MT-RNR1*                                     *RNR-TL1*    *MT-CO1*    *RNR-TS1*   *MT-TK*      *RNR-TE*    
  --------------------------------------------- ------------ ----------- ----------- ------------ ----------- ------------

After sequencing, high-quality reads were retrieved by filtering out adaptors, low-quality reads, and short sequences (\<40 bp). Data quality control standards were: 10× \> 95%, depth = 200 ± 30. The SOAPaligner program (SOAP v2.21) was used to align clean read sequences to the human reference genome (UCSC Genome Browser hg19). After removing duplicates with Picard software (v1.119), single nucleotide polymorphisms (SNPs) were identified using SOAPsnp v1.03. Subsequently, reads were realigned to the reference genome using the Burrows--Wheeler alignment program (0.7.12-r1044), and insertions or deletions (InDels) were detected by the HaplotypeCaller of GATK software (<https://software.broadinstitute.org/gatk/>, GATK-3.5) and filtered by VariantFiltration of GATK software. We annotated the identified SNPs and InDels using the Exome-assistant program. Short read alignment and candidate SNP and InDel validation were performed using MagicViewer.

We performed Sanger sequencing for all identified variants in the probands and their parents. PCR primers for Sanger sequencing were designed by Primer 3.0 software ([http://bioinfo.ut.ee/primer3-0.4.0/](https://bioinfo.ut.ee/primer3-0.4.0/)). Primers and PCR conditions for *GJB2* and *LOXHD1* are shown in [Table 1](#table1-0300060519884197){ref-type="table"}. DNA sequencing was performed on an ABI 3500DX Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

Bioinformatics analysis {#sec6-0300060519884197}
-----------------------

If a novel variant was found that was not reported in the Human Gene Variant Database ([http://www.hgmd.cf.ac.uk/](https://www.hgmd.cf.ac.uk/)) or ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>), we used PolyPhen2 ([http://genetics.bwh.harvard.edu/pph2](https://genetics.bwh.harvard.edu/pph2)) and PROVEAN ([http://provean.jcvi.org/index.php](https://provean.jcvi.org/index.php)) tools to predict its possible functional role. To exclude the possibility that the variant was a polymorphism, we also performed direct sequencing in 100 healthy controls.

Results {#sec7-0300060519884197}
=======

Variant analysis {#sec8-0300060519884197}
----------------

PCR and direct Sanger sequencing identified c.235delC (rs80338943)/c.299-300delAT (rs111033204) compound heterozygous variants of *GJB2* in the husband. c.235delC was inherited from his mother and c.299-300delAT was inherited from his father ([Figure 1](#fig1-0300060519884197){ref-type="fig"}).

![Results of Sanger sequencing. Compound heterozygous variants were detected in the proband.\
c.235delC (rs80338943, left)/c.299-300delAT (rs111033204, right) of *GJB2*. The father carried the heterozygous variant c.299-300delAT, while the mother and fetus carried the heterozygous variant c.235delC.](10.1177_0300060519884197-fig1){#fig1-0300060519884197}

No *GJB2* variants were identified in the wife, so targeted NGS was used to search for potential pathogenic variants. She was shown to carry c.1828G\>A (p.Glu610Lys, rs535637788)/c.2825-2827delAGA compound heterozygous variants of *LOXHD1*, with c.2825-2827delAGA inherited from her mother and c.1828G\>A from her father ([Figure 2](#fig2-0300060519884197){ref-type="fig"}). Her hearing loss is an extremely rare form known as DFNB77 (OMIM: 613079). Variant c.2825-2827delAGA has previously been reported to be associated with DFNB77,^[@bibr7-0300060519884197]^ but variant c.1828G\>A (p.E610K) was only reported in a Mexican-American individual in the 1000 Genomes database. It has not been reported to be associated with DFNB77. PCR and direct Sanger sequencing did not identify this variant in any of our 100 healthy controls.

![Results of Sanger sequencing. Compound heterozygous variants were detected in the proband.\
c.1828G\>A(p.Glu610Lys, rs535637788, left)/c.2825-2827delAGA (right) of *LOXHD1*. The father and fetus carried the heterozygous variant c.1828G\>A, while the mother carried the heterozygous variant c.2825-2827delAGA.](10.1177_0300060519884197-fig2){#fig2-0300060519884197}

Bioinformatics analysis score {#sec9-0300060519884197}
-----------------------------

PolyPhen2 and PROVEAN tools were used to evaluate the possible functional role of variant c.1828G\>A. PolyPhen2 gave a score of 1, suggesting that the site might be a damaging variation. The PROVEAN score was --3.203, and the site was considered "deleterious".

Pregnancy outcome {#sec10-0300060519884197}
-----------------

Following molecular analysis, we provided genetic counseling to the young couple with HL. We explained that their children were unlikely to have HL because they both carried different genetic variants. During their pregnancy, they underwent regular prenatal checkups which detected the presence of the c.235delC *GJB2* variant and the c.1828G\>A *LOXHD1* variant in the fetus ([Figures 1](#fig1-0300060519884197){ref-type="fig"} and [2](#fig2-0300060519884197){ref-type="fig"}). The baby was born in June 2018, and both ears passed the hearing screening test.

Discussion {#sec11-0300060519884197}
==========

We identified causative variants of HL in both individuals of a young Chinese couple. The variants of the husband were common and the c.2825-2827delAGA *LOXHD1* variant of the wife was previously associated with DFNB77; however, the c.1828G\>A *LOXHD1* variant of the wife has only been reported in a Mexican-American individual in the 1000 Genomes database, and not in the HGMD database or elsewhere. PolyPhen2 and PROVEAN tools suggested that it is a likely pathogenic variant.

*LOXHD1* is located on chromosome 18q12-q21 and contains at least 43 exons.^[@bibr8-0300060519884197]^ It encodes lipoxygenase homology domain 1-containing protein 1 which has 15 PLAT domains^[@bibr4-0300060519884197]^ that are involved in targeting proteins to the plasma membrane and mediating protein interactions.^[@bibr9-0300060519884197][@bibr10-0300060519884197][@bibr11-0300060519884197]--[@bibr12-0300060519884197]^ Mouse studies showed that the *Loxhd1* product is localized to the stereocilia of sensory hair cells, and that *Loxhd1* variants can induce deafness with defects in the stereocilia followed by hair cell degeneration.^[@bibr13-0300060519884197]^ This indicates that *LOXHD1* plays an important role in maintaining normal hair cell function.

Although DFNB77 has previously been associated with *LOXHD1* variants, it is a highly heterogeneous disease both phenotypically and genetically. More than 23 probands with DFNB77 have been reported worldwide on PubMed, and 37 different disease-causing variants have been identified ([Table 3](#table3-0300060519884197){ref-type="table"}).^[@bibr5-0300060519884197],[@bibr7-0300060519884197][@bibr8-0300060519884197][@bibr9-0300060519884197][@bibr10-0300060519884197][@bibr11-0300060519884197][@bibr12-0300060519884197][@bibr13-0300060519884197][@bibr14-0300060519884197][@bibr15-0300060519884197][@bibr16-0300060519884197][@bibr17-0300060519884197][@bibr18-0300060519884197][@bibr19-0300060519884197][@bibr20-0300060519884197]--[@bibr21-0300060519884197]^ Most of these probands come from Asia, suggesting that it has a high incidence of DFNB77. They show different auditory characteristics and audiometric phenotypes, varying from mild to profound and from stable to progressive sensorineural HL.^[@bibr5-0300060519884197],[@bibr7-0300060519884197][@bibr8-0300060519884197][@bibr9-0300060519884197][@bibr10-0300060519884197][@bibr11-0300060519884197][@bibr12-0300060519884197][@bibr13-0300060519884197][@bibr14-0300060519884197][@bibr15-0300060519884197][@bibr16-0300060519884197][@bibr17-0300060519884197][@bibr18-0300060519884197][@bibr19-0300060519884197][@bibr20-0300060519884197]--[@bibr21-0300060519884197]^ Animal studies revealed that homozygous missense variants of *Loxhd1* induced profound deafness while homozygous nonsense variants caused progressive HL.^[@bibr13-0300060519884197]^ However, Wesdorp et al.^[@bibr4-0300060519884197]^ found that the type of variant (nonsense or missense) did not associate with HL severity, and that the combination of a nonsense and missense variant could cause different audiometric phenotypes. Such research is limited, so correlations between *LOXHD1* variants and phenotypic characteristics of HL remain unclear.

###### 

Known *LOXHD1* variants causative of hearing loss.

![](10.1177_0300060519884197-table3)

  No.                              Nucleotide or amino acid change   Variant type   Zygosity   Type of HL        Progressiveness   Population
  -------------------------------- --------------------------------- -------------- ---------- ----------------- ----------------- -------------
  1^[@bibr5-0300060519884197]^     c.879 + 1G\>A                     Splice         Hom        Profound          Non-progressive   Japanese
  2^[@bibr5-0300060519884197]^     c.5869G\>T                        Nonsense       Het        Moderate-severe   Non-progressive   Japanese
  3^[@bibr5-0300060519884197]^     c.4480C\>T                        Nonsense       Het        Moderate-severe   Non-progressive   Japanese
  4^[@bibr7-0300060519884197]^     c.884C\>T                         Missense       Het        Moderate-severe   Progressive       --
  5^[@bibr7-0300060519884197]^     c.2825_2827delAGA                 Frameshift     Het        Moderate-severe   Progressive       --
  6^[@bibr7-0300060519884197]^     c.2797C\>T                        Nonsense       Het        Profound          Non-progressive   --
  7^[@bibr7-0300060519884197]^     c.1730T\>G                        Frameshift     Het        Profound          Non-progressive   --
  8^[@bibr7-0300060519884197]^     c.2722G\>A                        Missense       Het        Profound          Non-progressive   --
  9^[@bibr7-0300060519884197]^     c.3015_3017delCTT                 Frameshift     Het        Profound          Non-progressive   --
  10^[@bibr7-0300060519884197]^    c.766G\>T                         Nonsense       Het        Profound          Non-progressive   --
  11^[@bibr7-0300060519884197]^    c.3596T\>C                        Missense       Het        --                --                --
  12^[@bibr7-0300060519884197]^    c.2696G\>C                        Missense       Het        --                --                --
  13^[@bibr7-0300060519884197]^    c.4526G\>A                        Missense       Hom        Profound          Progressive       --
  14^[@bibr7-0300060519884197]^    c.4480C\>T                        Nonsense       Hom        Profound          Progressive       --
  15^[@bibr7-0300060519884197]^    c.3206G\>A                        Missense       Het        Moderate-severe   Non-progressive   --
  16^[@bibr7-0300060519884197]^    c.894T\>G                         Nonsense       Het        Moderate-severe   Non-progressive   --
  17^[@bibr7-0300060519884197]^    c.1501delG                        Frameshift     Het        Profound          Progressive       --
  18^[@bibr7-0300060519884197]^    c.1193G\>A                        Missense       Het        Profound          Progressive       --
  19^[@bibr7-0300060519884197]^    c.1147C\>T                        Nonsense       Het        Profound          Progressive       --
  20^[@bibr8-0300060519884197]^    c.4714C\>T                        Nonsense       Hom        Profound          Non-progressive   Jewish
  21^[@bibr9-0300060519884197]^    c.5674G\>T                        Missense       Het        Moderate-severe   Non-progressive   Japanese
  22^[@bibr9-0300060519884197]^    c.4212 + 1G\>A                    Splice         Het        Moderate-severe   Non-progressive   Japanese
  33^[@bibr13-0300060519884197]^   c.2008C\>T                        Nonsense       Hom        Moderate-severe   Progressive       Iranian
  24^[@bibr14-0300060519884197]^   p.Gly398Glu                       Missense       Het        Profound          Progressive       American
  25^[@bibr14-0300060519884197]^   p.Arg383X                         Nonsense       Het        Profound          Progressive       American
  26^[@bibr15-0300060519884197]^   c.2863G\>T                        Nonsense       Hom        --                --                Turkey
  27^[@bibr15-0300060519884197]^   c.4480C\>T                        Nonsense       Hom        --                --                Turkey
  28^[@bibr16-0300060519884197]^   c.1588C\>T                        Nonsense       Hom        Profound          Progressive       Qatar
  29^[@bibr17-0300060519884197]^   c.71delT                          Frameshift     Hom        --                --                Turkish
  30^[@bibr18-0300060519884197]^   c.3371G\>A                        Missense       Het        Profound          Non-progressive   Cameroonian
  31^[@bibr18-0300060519884197]^   c.3979T\>A                        Missense       Het        Profound          Non-progressive   Cameroonian
  32^[@bibr19-0300060519884197]^   c.1751C\>T                        Missense       Het        Moderate-severe   Progressive       Chinese
  33^[@bibr19-0300060519884197]^   c.5815G\>A                        Missense       Het        Moderate-severe   Progressive       Chinese
  34^[@bibr20-0300060519884197]^   p.A1406V                          Missense       Het        --                --                --
  35^[@bibr20-0300060519884197]^   p.K148\*                          Nonsense       Het        --                --                --
  36^[@bibr21-0300060519884197]^   c.797 G \> A                      Missense       Het        --                --                Chinese
  37\*                             c.1828G\>A                        Missense       Het        Profound          Non-progressive   Chinese

References shown as superscript numbers in first column; \* This study

Hom, homozygous; het, heterozygous

*LOXHD1* variants have not only been linked to HL but are also associated with late-onset Fuchs corneal dystrophy (FCD), a genetic disorder of the corneal endothelium.^[@bibr22-0300060519884197]^ A case--control study by Stehouwer et al.^[@bibr23-0300060519884197]^ reported a significant association between FCD and hearing disorders, but this should be investigated in larger sample sizes.^[@bibr22-0300060519884197]^ We believe that it is important to check for ophthalmology disorders in patients with HL caused by *LOXHD1* variants; however, we found no FCD phenotype in the current proband with *LOXHD1* variants.

In conclusion, we carried out molecular diagnosis in a young couple with congenital HL and identified different disease-causing variants in the two individuals. The husband had compound heterozygous variants of *GJB2*, while the wife had the extremely rare HL known as DFNB77 and compound heterozygous variants of *LOXHD1*. We followed up the pregnancy outcome of this couple, and report that both ears of their baby passed the hearing screening test. To the best of our knowledge, this is the third case reported in Chinese individuals and the first in the northwest of the country. PCR and direct Sanger sequencing cannot provide effective detection of diseases caused by such rare variants. However, with the development of molecular diagnostic technology, the cost of tests is decreasing and NGS will become a more effective way of providing accurate molecular diagnosis and genetic counseling for rare diseases.

Declaration of conflicting interest {#sec12-0300060519884197}
===================================

The authors declare that there is no conflict of interest.

Funding {#sec13-0300060519884197}
=======

This work was supported by the Gansu Natural Science Foundation (Grant Nos.: 18JR3RA036, 1606RJZA151), the Lanzhou Talent Innovation and Entrepreneurship Project (Grant No.: 2018-RC-95), and the National Population and Reproductive Health Science Data Center of the People's Republic of China (Grant No.: 2005DKA32408).

[^1]: These authors contributed equally to this work.
